TRIB2 IN AML

Investigating Trib2-induced Acute Myeloid Leukaemia

Coordinatore	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK    more  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Ms. Nome: Mary Cognome: Cusack Email: send email Telefono: -4902015 Fax: -4902686
Nazionalità Coordinatore	Ireland [IE]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IRG-2008
Funding Scheme	MC-IRG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-10-01   -   2013-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Ms. Nome: Mary Cognome: Cusack Email: send email Telefono: -4902015 Fax: -4902686	IE (CORK)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Acute Myeloid Leukemia (AML) is a poorly treatable leukemia in which a limited set of genes are involved. Trib2 is a gene that has not previously been associated with leukemia. My goal is to understand the pathogenesis of Trib2-induced acute myelogenous leukemia (AML). I identified Trib2 as a novel leukomogen that efficiently induces a clonal, transplantable AML in mice. Trib2 inhibits C/EBPalpha to cause AML, and elevated Trib2 expression associates with a cluster of human AML samples that have disrupted C/EBPalpha. This proposal will identify genetic events that cooperate with Trib2 and the Trib2 structural requirements for AML induction. Aim 1 will define the structural and functional domains of Trib2 that contribute to AML, and the domains required for C/EBPalpha inhibition. This will set the stage for Aim 2, which will identify the biochemical mechanism of Trib2-mediated C/EBPalpha degradation, and the mechanism involved in the Trib2-mediated degradation of other potential proteins. Aim 3 will ascertain cooperating events that contribute to Trib2-induced AML. The clonality of the Trib2-induced tumors suggests that the proviral integration site itself may activate genes that cooperate with Trib2. I will identify these proviral integration sites and determine whether genes at these sites synergize with Trib2 in AML pathogenesis. Together, my studies will reveal new pathogenic mechanisms and therapeutic opportunities in this aggressive cancer, which is not currently curable in the majority of patients.'